

**Outputs listed in DSMB Charter Appendix A****Safety Tables**

Progression-free survival (PFS) (as applicable)  
Overall survival (OS) (as applicable)

Cellular pharmacokinetics (PK) concentrations (if data available)

Tumor response

**Efficacy Listing****Efficacy Figures**

Progression Free Survival (as applicable)  
Overall Survival (as applicable)

**Outputs in the latest MM-001 DSMB Deliverables****DSMB Table #****DSMB Table Title**

Table 14.2.3.3.1

Table 14.2.8.2.1

**BB Graph Number**

Figure 14.2.3.2.1

Figure 14.2.2.2.1

Summary of Progression-free Survival Based on IMWG Criteria -Investigaor Assessment - Censoring Rules According to FDA Guideline - bb2121-treated Popu

Summary of bb2121 Pharmacokinetic Parameter Analysis Population

**BB Graph Title**

Kaplan-Meier Curve of Progression-free Sur IMWG Criteria-Investigator Assessment Ce on FDA Guideline - bb2121-Treated Popul

Kaplan-Meier Curve of Duration of Resp IMWG Criteria-Investigator Assessmen Population, FDA Censoring Rules, Resp

**Outputs listed in DSMB Charter Appendix A**

**Safety Tables**

	DSMB Table #	DSMB Table Title
Demographics	Table 14.1.6.2	Demographics and Baseline Characteristics - bb2121-treated Population
Subject Disposition	Table 14.1.3	Subject Disposition
Baseline Disease Characteristics	Table 14.1.7.2	Baseline Disease Characteristics - bb2121-treated Population
Multiple Myeloma Treatment History	Table 14.1.9.1	Prior Anti-Myeloma Therapies by Class - bb2121-treated Population
Bridging therapy by Drug Class	Table 14.1.10.1	Anti-Myeloma Bridging Therapies by Class - bb2121-treated Population
Exposure to Study Treatment (Including Lymphodepleting chemotherapy) conoam	Table 14.3.1.1.1	Duration of Anti-myeloma Bridging Therapies - bb2121-treated Population
	Table 14.3.1.2.2	bb2121 Administration - bb2121-treated Population
	Table 14.3.1.3.2	Lymphodepleting Chemotherapy (LD Chemo) Administration - bb2121-treated Population
Concomitant Medications	Table 14.3.2.1.1	Lymphodepleting Chemotherapy (LD Chemo) Dose Adjustment - bb2121-treated Population
Treatment-Emergent Adverse Events by System Organ Class (SOC) and Preferred Term (PT)	Table 14.3.2.2.1	Adverse Events (AEs) Summary - bb2121-treated Population
Treatment-Emergent Grade 3 or Higher Adverse Events Related to Study Drug by SOC (as applicable)	Table 14.3.2.2.2	Adverse Events (AEs) by System Organ Class and Preferred Term - Enrolled Population
Treatment-Emergent Grade 3 or Higher Adverse Events by SOC and PT	Table 14.3.2.3.1.1	Adverse Events (AEs) by System Organ Class and Preferred Term - bb2121-treated Population
Treatment-Emergent Serious Adverse Events by SOC and PT	Table 14.3.2.4.1.1	Grade 3/4 Adverse Events (AEs) by System Organ Class and Preferred Term - bb2121-treated Population
Treatment-Emergent Adverse Events Related to Study Drug by SOC and PT	Table 14.3.2.5.3.1	Serious Adverse Events (SAEs) by System Organ Class and Preferred Term - bb2121-treated Population
Treatment-Emergent Serious Adverse Events Related to Study Drug by SOC and PT		Adverse Events (AEs) Related to bb2121 by System Organ Class and Preferred Term - bb2121-treated Population
Treatment-Emergent Adverse Events leading to Study Drug Discontinuation		Adverse Events of Special Interest (AESI) by AESI Category and Preferred Term - bb2121-treated Population
Treatment-Emergent Adverse Events of Special Interest	Table 14.3.2.7.1.1	Serious Adverse Events of Special Interest (AESI) by AESI Category and Preferred Term - bb2121-treated Population
Treatment-Emergent Grade 3 or Higher Adverse Events of Special Interest	Table 14.3.2.7.2.1	Adverse Events of Special Interest (AESI) Related to bb2121 by AESI Category and Preferred Term - bb2121-treated Population
	Table 14.3.2.7.4.1	Summary of Cytokine Release Syndrome - bb2121-treated Population
	Table 14.3.2.8.1.1	Summary of Neurotoxicity - bb2121-treated Population
	Table 14.3.2.8.2.1	Summary of Deaths and Causes - Enrolled Population
	Table 14.3.2.10.1	Adverse Events (AEs) Leading to Death by System Organ Class and Preferred Term - bb2121-treated Population
Treatment-Emergent Adverse Events leading to death	Table 14.3.2.9.1.1	Time to Neutropenia Recovery from Infusion for Subjects with Last Lab within Month 1 of bb2121 Infusion Date Indicating Grade 3/4 Neutropenia - bb2121-treated Population
	Table 14.3.4.3.1.1	

Deaths

**Outputs listed in DSMB Charter Appendix A**

**Safety Tables**

**Outputs in the latest MM-001 DSMB Deliverables**

**DSMB Table Title**

Time to Thrombocytopenia Recovery from Infusion for Subjects with Last Lab within Month 1 of bb2121 Infusion Date Indicating Grade 3/4 Thrombocytopenia - bb2121-treated Population

Table 14.3.4.3.2.1

**bb2121 Drug Exposure and Comparator Drug Exposure (as applicable)**

**Safety Listings**

**DSMB Listing #**

**DSMB Listing Title**

Subject Disposition

Listing 16.2.1.1.1

Screen Failures - Screened Population

Demographics

Listing 16.2.1.2.1

Subject Disposition - bb2121-treated Population

Baseline Disease Characteristics

Multiple Myeloma Treatment History

Listing 16.2.4.8

Prior Bridging Therapies - bb2121-treated Population

Listing 16.2.5.3

bb2121 Infusion Dosing Records - bb2121-treated

Listing 16.2.5.1

Population

Listing 16.2.4.6.1

Leukapheresis - bb2121-treated Population

Listing 16.2.7.1.1.2

Prior and Concomitant Medication - bb2121-treated

Listing 16.2.7.1.2

Population

Concomitant medications

All Adverse Events - bb2121-treated Population

Adverse Events

Grade 3 or Higher Adverse Events

Serious Adverse Events

Serious Adverse Events - bb2121-treated Population

Adverse Events Related to Study Drug

Serious Adverse Events Related to Study Drug

Listing 16.2.7.2

Adverse Events of Special Interests - bb2121-treated Population

Listing 16.2.7.4

Death - Enrolled Population

Listing 16.2.8.1.1

Laboratory Results: Hematology - bb2121-treated

Listing 16.2.8.1.2

Population

Laboratory Results: Chemistry - bb2121-treated

Serum Inflammation (CRP and Ferritin)

Cytokine Profile (if available)

Blood VCN

**bb2121 Drug Exposure and Comparator Drug Exposure (if applicable)**

**DSMB Graph #**

**DSMB Graph Title**

Time to Neutropenia Recovery from Infusion for Subjects with Last Lab within Month 1 of bb2121 Infusion Date Indicating Grade 3/4 Neutropenia - bb2121-Treated Population

Figure 14.3.1.1

Time to Thrombocytopenia Recovery from Infusion for Subjects with Last Lab within Month 1 of bb2121 Infusion Date Indicating Grade 3/4 Thrombocytopenia - bb2121-Treated Population

Figure 14.3.1.2

**MM-001 Outputs in the BB**

**BB Table Title**

Summary of Best Overall Response based on IMWG Criteria - Investigator Assessment - bb2121-treated Population

**TLGs listed in DSMB Charter Appendix B**

**Efficacy Tables**

**BB Table Number**

Overall response rate (ORR)

Table 14.2.1.2.1

Minimal residual response (MRD)

Table 14.2.2.2.1

Time to Response and Duration of Response for Subjects with at Least Partial Response - Using IMWG Criteria - Investigator Assessment - bb2121-treated Population, FDA Censoring Rules, Responders only